Literature DB >> 24399851

A model too far.

Boris Freidlin1, Edward L Korn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24399851      PMCID： PMC3916743          DOI： 10.1093/jnci/djt368

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  11 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  The word "cancer": how language can corrupt thought.

Authors:  Barbara K Dunn; Sudhir Srivastava; Barnett S Kramer
Journal:  BMJ       Date:  2013-09-10

Review 3.  Cancer screening: the clash of science and intuition.

Authors:  Barnett S Kramer; Jennifer Miller Croswell
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

4.  Cancer screening campaigns--getting past uninformative persuasion.

Authors:  Steven Woloshin; Lisa M Schwartz; William C Black; Barnett S Kramer
Journal:  N Engl J Med       Date:  2012-11-01       Impact factor: 91.245

5.  Prostate cancer screening: what we know, don't know, and believe.

Authors:  Otis W Brawley
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

6.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

7.  Individualized estimates of overdiagnosis in screen-detected prostate cancer.

Authors:  Roman Gulati; Lurdes Y T Inoue; John L Gore; Jeffrey Katcher; Ruth Etzioni
Journal:  J Natl Cancer Inst       Date:  2014-01-07       Impact factor: 13.506

8.  Quality-of-life effects of prostate-specific antigen screening.

Authors:  Eveline A M Heijnsdijk; Elisabeth M Wever; Anssi Auvinen; Jonas Hugosson; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Arnauld Villers; Alvaro Páez; Sue M Moss; Marco Zappa; Teuvo L J Tammela; Tuukka Mäkinen; Sigrid Carlsson; Ida J Korfage; Marie-Louise Essink-Bot; Suzie J Otto; Gerrit Draisma; Chris H Bangma; Monique J Roobol; Fritz H Schröder; Harry J de Koning
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

9.  Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.

Authors:  Joy Melnikow; Michael LeFevre; Timothy J Wilt; Virginia A Moyer
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983

10.  Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.

Authors:  Ruth Etzioni; Roman Gulati; Matt R Cooperberg; David M Penson; Noel S Weiss; Ian M Thompson
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983
View more
  2 in total

Review 1.  Missteps in Current Estimates of Cancer Overdiagnosis.

Authors:  Christoph I Lee; Ruth Etzioni
Journal:  Acad Radiol       Date:  2016-11-25       Impact factor: 3.173

Review 2.  Targeted Cancer Screening in Average-Risk Individuals.

Authors:  Pamela M Marcus; Andrew N Freedman; Muin J Khoury
Journal:  Am J Prev Med       Date:  2015-07-10       Impact factor: 5.043
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.